Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544410 | 0.84 | DRD3 (0.46) | ALDH1A1DRD3KMT2AMAPT | |
| SCHEMBL5963204 | 0.82 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTCASP3GLS | |
| SCHEMBL31425560 | 0.82 | ALDH1A1 (0.52) | ALDH1A1KMT2AMAPTCASP3GLS | |
| SCHEMBL9342981 | 0.81 | ALDH1A1 (0.52) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL31758137 | 0.81 | ALDH1A1 (0.52) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL2517320 | 0.81 | ALDH1A1 (0.50) | ALDH1A1DRD3KMT2AMAPTCASP3 | |
| SCHEMBL31461466 | 0.80 | CHRM2 (0.50) | KMT2A | |
| SCHEMBL19974506 | 0.80 | CHRM2 (0.50) | KMT2A | |
| SCHEMBL14928796 | 0.79 | ALDH1A1 (0.49) | ALDH1A1DRD3KMT2ACASP3CA12 | |
| SCHEMBL14393320 | 0.79 | ALDH1A1 (0.49) | ALDH1A1DRD3KMT2ACASP3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| EP-2576520-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE Healthcare UK Limited (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| CN-102918031-A | Radiolabeled compounds and methods thereof | GE HEALTHCARE LTD | 2013-02-06 | — | — | CN | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| US-6432946-B1 | PSYCHOLOGICAL DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | disclosed |
| EP-1027347-A2 | 3-AMINOALKYLAMINO-2H-1,4-BENZOXA(THIA-)ZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NEUROGEN CORPORATION (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6100255-A | BIND SELECTIVELY WITH HIGH AFFINITY TO THE DOPAMINE D4 RECEPTOR SUBTYPE; USE IN TREATING VARIOUS NEUROPSYCHOLOGICAL DISORDERS, INCLUDING ALZHEIMER'S DISEASE, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR TARDIVE DYSKINESIA | NEUROGEN CORPORATION (US) | 2000-08-08 | — | — | US | disclosed |
| WO-1999023092-A2 | 3-AMINOALKYLAMINO-2H-1,4-BENZOXA(THIA-)ZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NEUROGEN CORPORATION (US) | 1999-05-14 | — | — | WO | disclosed |
| US-5314884-A | Antidepressants, anxiolytic agents | TROPONWERKE GMBH & CO. (DE) | 1994-05-24 | — | — | US | disclosed |
| EP-0278621-B1 | SUBSTITUTED AMINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | ALDH1A1 702/4885DRD3 102/4885KMT2A 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.